KOSDAQBiotech & Pharma240550

DongBang Medical

₩5,030▼ 1.76%2026-11-18 close
Market Cap
₩105.3B
Turnover
₩200M
Volume
40K
Shares out.
20.9M
PER
7.5×
PBR
0.9×
EPS
₩744
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Export Growth in Aesthetic Fillers Versus Softer Quarterly Profit

Export expansion in aesthetic HA fillers lifted DongBang Medical's 2025 operating profit and net profit attributable to controlling shareholders, but that attributable profit has declined for two consecutive quarters from the 2026 second quarter through the third quarter.

  1. 1

    Full-year 2025 revenue reached KRW 113.5 billion, the largest of the three years shown, and operating profit rose 13.0% year on year to KRW 17 billion.

  2. 2

    The debt-to-equity ratio fell from 148.3% in 2023 to 48.8% in 2025, indicating a stronger balance sheet.

  3. 3

    Third-quarter 2026 revenue was KRW 29.3 billion, down 2.4% from a year earlier, and net profit attributable to controlling shareholders was KRW 2.4 billion, down 19.1% year on year.

  4. 4

    HA fillers, including the product that recently received Brazil's ANVISA marketing approval, and sales through Xinyang Group in China are cited as the main pillars of overseas revenue.

  5. 5

    Choi Nak-yi was appointed CEO in March 2026, and the next checkpoint is the operating margin and attributable net profit in the 2026 annual report.

02

Business structure

DongBang Medical was founded in 1985 as a maker of oriental medicine acupuncture needles and expanded into aesthetic medical devices such as fillers and absorbable sutures. It listed on KOSDAQ on February 13, 2025. The business has two segments, oriental medical devices and aesthetic medical devices.

The company says it holds the number one domestic market share in single-use oriental acupuncture needles and cupping cups.

Money Today reported in June 2025 that the aesthetic segment's revenue share rose from 51.2% in 2022 to 59.3% in 2024, but a separate Edaily report gave the split the other way around (oriental 59%, aesthetic 41%), so the share figures differ by source.

The aesthetic core is its hyaluronic acid (HA) filler line ELASTY and absorbable PDO lifting threads. HA filler revenue was KRW 23.1 billion in 2024, up 47.4% year on year, and lifting thread revenue was KRW 14 billion, up 7.4%. The company exports HA fillers to 44 countries.

In China it sells through Xinyang Group, and in India it holds exclusive supply rights reported at about USD 9 million over three years including automatic extensions. In Brazil, it received ANVISA marketing approval for the PHD HA Filler together with partner PHD.

Around April 2026 it signed a distribution agreement for an ECM skin booster product in Korea. Eugene Investment & Securities has cited the large partners it holds in China, including IMEIK, a leading aesthetic medical company in China, as a growth factor.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩30B₩4.1B13.6%
2025Q4₩29.8B₩5.5B18.6%
2026Q1₩31.4B₩6.1B19.3%
2026Q2₩33.9B₩6.4B18.7%
2026Q3₩29.3B₩5.4B18.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩90.9B₩16.5B₩9.8B18.1%20.9%148.3%
2024₩105.1B₩15B₩2.9B14.3%3.6%86.3%
2025₩113.5B₩17B₩11.7B15.0%9.5%48.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from 909 eok won in 2023 (1 eok = 100 million won) to 1,051 eok won in 2024 (up 15.7% year on year) and 1,135 eok won in 2025 (up 8.0% year on year), increasing for two consecutive years from 2024 to 2025. Among 2023–2025, the largest year was 2025 and the smallest was 2023.

Operating profit fell from 165 eok won in 2023 to 150 eok won in 2024 (down 8.7% year on year), then recovered to 170 eok won in 2025 (up 13.0% year on year).

Regarding the 2024 decline, Edaily analyzed that results for core products such as fillers, lifting threads, and Korean medicine acupuncture needles improved, but results for other Korean medicine supplies decreased. The operating margin was 18.1% in 2023, 14.3% in 2024, and 15.0% in 2025.

Net profit attributable to controlling shareholders fluctuated widely: 97.7 eok won in 2023, 29.1 eok won in 2024 (down 70.2% year on year), and 117 eok won in 2025 (up 301.6% year on year).

Over the same period, net profit including non-controlling interests was 97.3 eok won, 31.3 eok won, and 114 eok won, which differs from net profit attributable to controlling shareholders.

In 2024, the decline in net profit attributable to controlling shareholders (70.2%) was far larger than the decline in operating profit (8.7%), so items below operating profit must be examined together to interpret the result.

Operating cash flow was 62.8 eok won in 2023, 185 eok won in 2024, and 120 eok won in 2025, decreasing in 2025. Looking at the quarterly trend, operating profit rose from 40.6 eok won on revenue of 300 eok won in Q3 2025 to 55.3 eok won on revenue of 298 eok won in Q4 2025.

In Q1 2026, revenue was 314 eok won, operating profit was 60.5 eok won, and net profit attributable to controlling shareholders was 54 eok won, which was the peak for that measure.

Revenue in Q2 2026 was 339 eok won, the largest of the last five quarters, but net profit attributable to controlling shareholders fell to 41.4 eok won. Revenue in Q3 2026 was 293 eok won (down 13.8% from the previous quarter), and operating profit was 54.3 eok won (up 33.7% from the same quarter a year earlier).

Net profit attributable to controlling shareholders in the same quarter was 24 eok won (down 19.1% from the same quarter a year earlier). The sum of net profit attributable to controlling shareholders for the last four quarters (Q4 2025 to Q3 2026) is 156 eok won.

05

Industry analysis

The company's core markets are the aesthetic HA filler market and the domestic oriental medical device market. Edaily, citing KOTRA data, reported that China's hyaluronic acid filler market is expected to grow from about 6.4 billion yuan in 2021 to 44.1 billion yuan in 2030, a compound annual growth rate of 14%.

The same report projected the global aesthetic medical market rising from USD 99 billion in 2021 to USD 321 billion in 2030. These are industry-wide forecasts and do not translate directly into the company's revenue. The oriental medicine segment is largely domestic and rests on its number one domestic position.

The company says it focuses on domestic sales for cupping cups. Approval procedures differ by export market, so regulatory approvals in Brazil and China determine how fast export revenue can scale. Xinyang Group in China and IMEIK, a leading aesthetic medical company in China, are cited as partners.

Eugene Investment & Securities treated this partnership as a growth factor. However, revenue can swing quarter to quarter depending on partner sell-through, so dependence on specific countries is a point to monitor.

06

Outlook

In Brazil, with ANVISA approval for the PHD HA Filler in hand, the next items to confirm are the start of sales and whether a joint venture with partner PHD is formed. A 2025 report expected a full push into the Brazilian market through steps such as a joint venture.

In China, higher sales to Xinyang Group of the lidocaine-containing HA filler were cited as a second-half revenue driver. A 2025 report said full-scale supply of HA fillers in China is planned from 2027.

For Indonesia, the oriental needle production line with monthly capacity of 300 million units was expected to run in 2026, and whether that lifts revenue and margins is the key check for the oriental segment. On new products, the company said it is developing PN+HA, CaHA and PLLA fillers.

Distribution of the ECM skin booster was presented as a way to widen the premium aesthetic lineup. The company stated in a 2025 report that it aims to raise the aesthetic segment's revenue share to 80% by 2028.

Third-quarter 2026 revenue fell from the prior quarter, and whether that drop is temporary cannot be judged from disclosed figures alone. The next annual report should show whether export growth offset the quarterly decline.

07

Valuation

PER
7.5×
PBR
0.9×
ROE
12.3%
EPS
₩744
BPS
₩6,378
Dividend per share
₩0

The price-to-book ratio sits below 1x, which means the share price trades at a discount to net assets. Total equity was KRW 125.3 billion at the end of 2025, of which KRW 122.9 billion belongs to controlling shareholders. The dividend yield is below the industry average.

On an earnings basis, the reference point could be attributable net profit for the last four quarters, which totals KRW 15.6 billion. Because attributable profit moved sharply from KRW 2.91 billion in 2024 to KRW 11.7 billion in 2025, the earnings multiple depends heavily on the period chosen.

The 2025 profit recovery means an earnings multiple on 2025 results is lower than one on 2024 results. Profit has declined over the last two quarters, so the trailing earnings multiple could move again with quarterly trends. Comparing the price with net assets and the earnings period is the factual starting point.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Wider overseas filler channels

The company exports HA fillers to 44 countries and has widened its channels through Xinyang Group in China, exclusive supply in India and the PHD partnership in Brazil. The PHD HA Filler recently received ANVISA marketing approval.

Eugene Investment & Securities cited large partners in China as a basis for expecting sizable revenue growth. The bull case rests on approvals converting into actual sales.

Stronger balance sheet and profit recovery

The debt-to-equity ratio fell from 148.3% in 2023 to 48.8% in 2025, and total equity was KRW 125.3 billion at the end of 2025. Net profit attributable to controlling shareholders recovered from KRW 2.91 billion in 2024 to KRW 11.7 billion in 2025. Operating profit rose 13.0% to KRW 17 billion in 2025. With more financial room, continued overseas approvals could support further investment.

Rising weight of the aesthetic segment

Money Today reported that aesthetic segment revenue rose from KRW 41.7 billion in 2022 to KRW 62.3 billion in 2024. Reports put the aesthetic share at 59.3% in 2024. The company has set a goal of raising the aesthetic share to 80% by 2028. If this shift happens, the growth engine of the company changes direction, which is the bull-case reading.

09

Bear factors

Consecutive quarterly profit declines

Net profit attributable to controlling shareholders fell from KRW 5.4 billion in the first quarter of 2026 to KRW 4.14 billion in the second quarter and KRW 2.4 billion in the third, two quarters of consecutive decline. Third-quarter revenue fell 13.8% from the prior quarter and 2.4% from a year earlier.

Operating profit rose year on year but attributable net profit fell 19.1%, so the operating gain did not carry through to the bottom line. Whether this continues is the core bear-case question.

Earnings volatility and softer cash flow

Net profit attributable to controlling shareholders fell 70.2% in 2024, against an 8.7% drop in operating profit. Operating cash flow fell from KRW 18.5 billion in 2024 to KRW 12 billion in 2025. The operating margin dropped from 18.1% in 2023 to 14.3% in 2024 and only recovered to 15.0% in 2025. Large swings in earnings make shareholder return capacity harder to predict, which is the bear-case concern.

Oriental segment margins and China sales swings

NH Investment & Securities said second-quarter 2025 results fell slightly short of expectations because of weaker profitability in the oriental medical segment and softer China filler sales. The same report also cited a factory pause tied to an FDA continuation review and the transfer of production equipment.

China sales move with partner orders, so heavy dependence on specific partners can enlarge quarterly swings. If these factors recur, the bull case's assumptions could weaken.

10

Risk factors

Regulatory approval risk

NH Investment & Securities named delays in key-country approvals as a risk factor for the share price. Overseas filler revenue lags as approvals move through regulators such as ANVISA in Brazil and NMPA in China. Delays push back revenue recognition in planned channels and can affect partner terms. The company's overseas growth plan depends on the timing of these approvals.

Partner and export concentration risk

Overseas revenue relies on specific partners, including Xinyang Group, the Indian supply channel and PHD. China sales move with Xinyang Group's order volume. Inventory adjustments or changes in contract terms at partners could cause quarterly revenue swings. Exchange rate moves can also affect export revenue that is priced in foreign currency.

Management change and governance

On March 10, 2026, the board appointed Choi Nak-yi as CEO after Kim Keun-sik resigned. Overseas approvals and new product development are continuing through this leadership change, so continuity of execution is a point to monitor. Disclosures in early 2026 also showed executives exercising share purchase claim rights. These facts bear on the company's strategic direction and management continuity.

11

What to watch next

  1. After November 2026 (date not set)

    The start of sales for the PHD HA Filler in Brazil and whether a joint venture with partner PHD is formed. This shows whether Brazilian sales start contributing to the export mix.

  2. By March 31, 2027

    The 2026 annual report on DART. It is the checkpoint for the full-year 2026 operating margin and attributable net profit, to compare against the KRW 15.6 billion four-quarter total.

  3. By May 15, 2027

    The first-quarter 2027 quarterly report. It shows whether the decline in attributable net profit that began in the second quarter of 2026 reverses.

  4. During 2027

    Whether full-scale supply of HA fillers in China begins. A 2025 report said supply is planned from 2027, and this marks a possible shift in the China revenue mix.

12

Overall view

DongBang Medical built its business on the number one domestic position in oriental medical devices and has been expanding exports of aesthetic HA fillers. Full-year 2025 revenue was KRW 113.5 billion and operating profit was KRW 17 billion, reversing the 2024 decline, and the debt-to-equity ratio fell to 48.8%.

On the other side, attributable net profit has declined for two consecutive quarters from the second quarter through the third quarter of 2026, and third-quarter revenue fell 2.4% year on year.

Bull-case drivers include the PHD HA Filler approval in Brazil, sales through Xinyang Group in China and exclusive supply in India. Bear-case drivers include approval delays, partner concentration and earnings volatility.

The share price sits at a discount to net assets, but the earnings multiple varies sharply by the period chosen, so the earnings trend needs to be read alongside it. The next checkpoints are the operating margin and attributable net profit in the 2026 annual report and whether Brazilian sales start. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. pharm.edaily.co.kr
  3. pharm.edaily.co.kr
  4. pharm.edaily.co.kr
  5. etoday.co.kr
  6. mt.co.kr
  7. eureka.hankyung.com
  8. dailyinvest.kr
  9. medigatenews.com
  10. news.nate.com
  11. newsprime.co.kr
  12. news.nate.com
  13. news.nate.com
  14. thevc.kr
  15. edaily.co.kr
  16. vegannews.co.kr
  17. m.news.nate.com
  18. news.nate.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis